| A Study of Usage of Brigatinib in the Treatment of Adult Participants for Approved Indications In South Korea (NCT04592523) | Takeda | 2019-09-05 |
| A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer (NCT04077463) | Janssen Research & Development, LLC | 2019-09-04 |
| Real World Evidence of Long-term Safety and Efficacy in Patients Treated With Durvalumab After Concurrent Chemoradiation for Unresectable Stage III NSCLC (NCT03995875) | AstraZeneca | 2019-07-25 |
| ctDNA Guided Treatment of Early Resistance to Targeted Treatment (NCT04148066) | The Netherlands Cancer Institute | 2019-07-17 |
| Stage III NSCLC RWE in Chinese Patients (NCT04023812) | AstraZeneca | 2019-07-16 |
| A Study of Nivolumab +/- Docetaxel in Patients Previously Treated With Advanced or Metastatic NSCLC (NCT04023617) | Peking University Cancer Hospital & Institute | 2019-07-08 |
| Development and Analysis of a Stool Bank for Cancer Patients (NCT04291755) | Persephone Biosciences | 2019-06-28 |
| Platinum-Based Chemotherapy Plus Ramucirumab in Patients With Advanced NSCLC Who Have Progressed on First Line Anti-PD-1 Immunotherapy (NCT03904108) | ROGER S KERESZTES MD | 2019-06-27 |
| A Study of mRNA-5671/V941 as Monotherapy and in Combination With Pembrolizumab (V941-001) (NCT03948763) | Merck Sharp & Dohme LLC | 2019-06-26 |
| Korea Osimertinib Real World Evidence Study to Assess Safety and Efficacy - PLUS (NCT03918304) | AstraZeneca | 2019-06-11 |
| Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors. (NCT03891953) | Novartis Pharmaceuticals | 2019-05-07 |
| A Study of Lorlatinib in ALK Inhibitor-Treated ALK-Positive NSCLC in China (NCT03909971) | Pfizer | 2019-04-28 |
| SinTilimab After Radiation (STAR Study) (NCT04167657) | Peking Union Medical College Hospital | 2019-04-15 |
| M7824 in Combination With Chemotherapy in Stage IV Non-small Cell Lung Cancer (NSCLC) (NCT03840915) | EMD Serono Research & Development Institute, Inc. | 2019-04-02 |
| Neoantigen-primed DC Vaccines Therapy for Refractory Lung Cancer (NCT03871205) | Shenzhen People's Hospital | 2019-04-01 |
| Concurrent Nab-P/Carboplatin and Thoracic Radiotherapy in Squamous Cell Lung Cancer (NCT03802058) | Wuhan University | 2019-03-20 |
| Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation (NCT03833154) | AstraZeneca | 2019-03-06 |
| NSCLC Isotoxic Hypofractionated Radiotherapy (NCT03606291) | The Second Hospital of Hebei Medical University | 2019-02-01 |
| NSCLC Isotoxic Hypofractionated Chemoradiotherapy (NCT03606239) | The Second Hospital of Hebei Medical University | 2019-02-01 |
| Study to Evaluate the Safety of Pembrolizumab in Participants With Unresectable or Metastatic Melanoma or Non-small Cell Lung Cancer in India (MK-3475-593/KEYNOTE-593) (NCT03715205) | Merck Sharp & Dohme LLC | 2019-01-31 |
| This Study Tests How BI 754111 is Distributed in Patients With Advanced Non-small Cell Lung Cancer or Patients With Head and Neck Cancer Who Are Treated With BI 754091 (NCT03780725) | Boehringer Ingelheim | 2019-01-22 |
| Efficacy and Safety of PEMbrolizumab PD-L1-positive (>50% of Tumor Cells), Advanced NSCL Cancer(PEMBREIZH) (NCT05321212) | University Hospital, Brest | 2019-01-02 |
| Study of Capmatinib and Spartalizumab Combination Therapy vs Docetaxel in Non-small Cell Lung Cancer (NCT03647488) | Novartis Pharmaceuticals | 2018-12-26 |
| A Study Comparing Immunotherapy With Chemotherapy in the Treatment of Elderly Patients With Advanced NSCLC (MILES-5) (NCT03975114) | National Cancer Institute, Naples | 2018-12-20 |
| Influence of Biopsy Technique on Moleculargenetic Tumor Characterisation in NSCLC (NCT03971175) | University Hospital Tuebingen | 2018-12-19 |
| T-DM1 and Osimertinib Combination Treatment to Target HER2 Bypass Track Resistance in EGFR Mutation Positive NSCLC (NCT03784599) | The Netherlands Cancer Institute | 2018-12-18 |
| Consolidation Sintilimab After Concurrent Chemoradiation in Patients With Unresectable Stage III NSCLC (NCT03884192) | Shandong Cancer Hospital and Institute | 2018-12-12 |
| Aggressive Thoracic Radiotherapy for Stage Ⅳ Non Small Cell Lung Cancer (NCT03565120) | yu gengsheng | 2018-12-10 |
| Vitamin C and Tyrosine Kinase Inhibitor in Lung Cancer Patients With Epidermal Growth Factor Receptor Mutations (NCT03799094) | Clifford Hospital, Guangzhou, China | 2018-12-05 |
| Afatinib and Cetuximab in Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Positive Non-small-cell Lung Cancer (NCT03727724) | The Netherlands Cancer Institute | 2018-12-04 |
| A Study of Pemetrexed Maintenance With or Without ADXS11-001 Immunotherapy in Patients With Human Papillomavirus Positive (HPV+), NSCLC Following First-Line Induction Chemotherapy (NCT02531854) | Advaxis, Inc. | 2018-12-01 |
| Evaluation in Real World of Molecular Testing and Treatment Patterns for EGFR Mutation in Lung Cancer Patients (NCT03721289) | AstraZeneca | 2018-11-29 |
| A Study of Durvalumab as Consolidation Therapy in Non-Small Cell Lung Cancer Patients (NCT03706690) | AstraZeneca | 2018-11-27 |
| Radiation and Chemotherapy With Ipilimumab Followed by Nivolumab for Patients With Stage III Unresectable Non-Small Cell Lung Cancer (NSCLC) (NCT03663166) | H. Lee Moffitt Cancer Center and Research Institute | 2018-11-20 |
| A Phase 2 Study Adding Ascorbate to Chemotherapy and Radiation Therapy for NSCLC (NCT02905591) | Joseph J. Cullen, MD, FACS | 2018-11-16 |
| Denosumab and Nivolumab Combination As 2d-line Therapy in Stage IV NSC Lung Cancer with Bone Metastases (DENIVOS) (NCT03669523) | Centre Hospitalier Annecy Genevois | 2018-11-06 |
| Shenlingcao Oral Liquid for Patients With Stage II or IIIA NSCLC (NCT03712969) | West China Hospital | 2018-11-05 |
| Concurrent Chemoradiotherapy Combination With Anlotinib for Unresectable Stage III NSCLC Patients (NCT03672136) | Shandong Cancer Hospital and Institute | 2018-11-01 |
| Surveillance With PET/CT and Liquid Biopsies of Stage I-III Lung Cancer Patients After Completion of Definitive Therapy (NCT03740126) | Rigshospitalet, Denmark | 2018-10-25 |
| Clinical Research of S-1 Versus Pemetrexed in the Maintenance Treatment of Advanced NSNSCLC (NCT03700333) | The First Affiliated Hospital with Nanjing Medical University | 2018-10-20 |
| Study to Describe Treatment Patterns and Outcomes in EGFRm NSCLC Patients in Belgium (NCT03761901) | AstraZeneca | 2018-09-21 |
| Immune Checkpoint Inhibitors in Advanced Non-small Cell Lung Cancer and Discovery of New Biomarkers (NCT03658460) | Aalborg University Hospital | 2018-08-22 |
| A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer (NCT03456076) | Hoffmann-La Roche | 2018-08-16 |
| Osimertinib In EGFR Mutant Lung Cancer (NCT03586453) | Dana-Farber Cancer Institute | 2018-08-13 |
| The Addition of Metformin to Definitive Radiotherapy in Patients With Stage III NSCLC (NCT04170959) | ethisch.comite@uza.be | 2018-07-30 |
| Phase III Study of Nazartinib (EGF816) Versus Erlotinib/Gefitinib in First-line Locally Advanced / Metastatic NSCLC With EGFR Activating Mutations (NCT03529084) | Novartis Pharmaceuticals | 2018-07-24 |
| A Study to Determine Progression-free Survival (PFS) and Evaluate Participant Experience for Participants With Metastatic Anaplastic Lymphoma Kinase-positive (ALK+) Non-Small Cell Lung Cancer (NSCLC) Treated With Anaplastic Lymphoma Kinase (ALK) Inhibitors (NCT03546894) | Takeda | 2018-07-23 |
| Radiomics Multifactorial Biomarker for Pulmonary Nodules (NCT03872362) | Maastricht University | 2018-07-11 |
| Phase II Umbrella Study Directed by Next Generation Sequencing (NCT03574402) | Guangdong Association of Clinical Trials | 2018-07-09 |
| E GFR TKI and EGF-P TI C Ombination in EGFR mutA nt NSCL C (NCT03623750) | Instituto Oncológico Dr Rosell | 2018-07-06 |
| Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors (NCT03485209) | Seagen, a wholly owned subsidiary of Pfizer | 2018-06-25 |
| Study in Patients With Tumours Requiring Arginine to Assess ADI-PEG 20 With Atezolizumab, Pemetrexed and Carboplatin (NCT03498222) | Queen Mary University of London | 2018-06-01 |
| Oleclumab (MEDI9447) Epidermal Growth Factor Receptor Mutant (EGFRm) Non-small Cell Lung Cancer (NSCLC) Novel Combination Study (NCT03381274) | MedImmune LLC | 2018-05-08 |
| A Personal Cancer Vaccine (NEO-PV-01) With Pembrolizumab and Chemotherapy for Patients With Lung Cancer (NCT03380871) | BioNTech US Inc. | 2018-05-04 |
| Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid Tumors (NCT03509012) | AstraZeneca | 2018-05-02 |
| A Study of ZN-e4 in Subjects With Epidermal Growth Factor Receptor Mutated Non-Small Cell Lung Cancer (NCT03446417) | Zeno Pharmaceuticals, Inc. | 2018-04-20 |
| Oral Decitabine and Tetrahydrouridine as Epigenetic Priming for Pembrolizumab-Mediated Immune Checkpoint Blockade in Patients With Inoperable, or Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancers and Esophageal Carcinomas (NCT03233724) | National Cancer Institute (NCI) | 2018-04-11 |
| Autologous Tcm Cells Immunotherapy in Patients With Non-Small Cell Lung Cancer (NSCLC) (NCT03432156) | Beijing Friendship Hospital | 2018-04-03 |
| National Network Genomic Medicine Lung Cancer, Germany (NCT05934032) | Prof. Dr. Juergen Wolf | 2018-04-01 |
| G1T38, a CDK 4/6 Inhibitor, in Combination With Osimertinib in EGFR-Mutant Non-Small Cell Lung Cancer (NCT03455829) | G1 Therapeutics, Inc. | 2018-03-29 |
| Real-World Study on Adjuvant Therapy Combined With Shenlingcao Oral Liquid in Patients for Stage II and IIIA Non-small Cell Lung Cancer After Radical Resection (NCT03479294) | West China Hospital | 2018-03-28 |
| Randomized Comparative Study of Erlotinib and Pemetrexed in the Maintenance Treatment of Advanced Lung Cancer Patients. (NCT03460678) | Hikma Pharmaceuticals LLC | 2018-02-28 |
| Study of Boserolimab (MK-5890) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Adults With Advanced Solid Tumors (MK-5890-001) (NCT03396445) | Merck Sharp & Dohme LLC | 2018-02-18 |
| Chemotherapy Combination With Local Radiotherapy and rhGM-CSF for Oligometastatic Stage IV NSCLC Patients (NCT03489616) | Shandong Cancer Hospital and Institute | 2018-01-15 |
| Afatinib Osimertinib Sequencing NIS (NCT03370770) | Boehringer Ingelheim | 2017-12-28 |
| A Study of the Safety of Atezolizumab in Participants With Locally Advanced or Metastatic Non Small Cell Lung Cancer in Argentina (NCT03321695) | Hoffmann-La Roche | 2017-12-27 |
| A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer) (NCT03337698) | Hoffmann-La Roche | 2017-12-27 |
| Prospective Trial of Induction Immunotherapy in Locally Advanced or Oligometastatic NSCLC Without a Primary Curative Option (NCT04926584) | Klinikum Esslingen | 2017-12-15 |
| Durvalumab (MEDI4736) in Frail and Elder Patients With Metastatic NSCLC (DURATION) (NCT03345810) | AIO-Studien-gGmbH | 2017-12-14 |
| Study of Pembrolizumab Given With Ipilimumab or Placebo in Participants With Untreated Metastatic Non-Small Cell Lung Cancer (NSCLC) (MK-3475-598/KEYNOTE-598) (NCT03302234) | Merck Sharp & Dohme LLC | 2017-12-14 |
| A Study of Atezolizumab (Tecentriq®) in Ministry of Food and Drug Safety (MFDS)-Approved Indication(s) (NCT03232593) | Hoffmann-La Roche | 2017-11-29 |
| Comparison of Post-operative Pain and Quality of Life Between Subxiphoid and Intercostal VATS for Lung Cancer (NCT03331588) | Shanghai Pulmonary Hospital, Shanghai, China | 2017-11-10 |
| Study of Carotuximab (TRC105) Plus Nivolumab in Patients With Metastatic NSCLC (NCT03181308) | Tracon Pharmaceuticals Inc. | 2017-11-09 |
| Testing Afatinib in Combination With Pembrolizumab in Patients With Squamous Cell Carcinoma of the Lung (NCT03157089) | Boehringer Ingelheim | 2017-11-02 |
| Atezolizumab Immunotherapy in Patients With Advanced NSCLC (NCT03102242) | Alliance Foundation Trials, LLC. | 2017-11-01 |
| A Study of Atezolizumab (Tecentriq) to Investigate Long-term Safety and Efficacy in Previously-treated Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) (NCT03285763) | Hoffmann-La Roche | 2017-10-25 |
| A Study to Evaluate the Safety, Tolerability, and Activity of TAK-931 in Participants With Metastatic Pancreatic Cancer, Metastatic Colorectal Cancer, and Other Advanced Solid Tumors (NCT03261947) | Millennium Pharmaceuticals, Inc. | 2017-10-25 |
| Astra Zeneca (Immuno Stereotactic Ablative Body Radiotherapy) ISABR Study: Randomized Phase I/II Study of Stereotactic Body Radiotherapy (NCT03148327) | Jonsson Comprehensive Cancer Center | 2017-10-11 |
| A Dose-Finding Study of the Second Mitochondrial Activator of Caspases (SMAC) Mimetic Debio 1143 When Given in Combination With Avelumab to Participants With Advanced Solid Malignancies and to Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) After Platinum-Based Therapy (NCT03270176) | Debiopharm International SA | 2017-10-10 |
| VX15/2503 in Combination With Avelumab in Advanced Non-small Cell Lung Cancer (NCT03268057) | Vaccinex Inc. | 2017-10-05 |
| IMRT and Timing in Combination With EGFRTKI for Stage IV Non-small-cell Lung Cancer (NCT03258671) | LuBing | 2017-10-01 |
| Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers (NCT03212404) | Checkpoint Therapeutics, Inc. | 2017-09-20 |
| Dexamethasone, Flurbiprofen Axetil and Long-term Survival After Lung Cancer Surgery (NCT03172988) | Peking University First Hospital | 2017-08-02 |
| Dexamethasone, Flurbiprofen Axetil and Delirium After Lung Cancer Surgery (NCT03200600) | Peking University First Hospital | 2017-08-02 |
| Bevacizumab and Erlotinib in Lung Cancer With Brain Metastases, a Phase II Trial (NCT02655536) | National Taiwan University Hospital | 2017-08-01 |
| Ipilimumab and Nivolumab in Patients With Anti-PD-1-axis Therapy-resistant Advanced Non-small Cell Lung Cancer. (NCT03262779) | Yale University | 2017-07-20 |
| A Study of the Efficacy and Safety of Alectinib in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NCT03155009) | Hoffmann-La Roche | 2017-07-10 |
| Study of FAK (Defactinib) and PD-1 (Pembrolizumab) Inhibition in Advanced Solid Malignancies (FAK-PD1) (NCT02758587) | NHS Greater Glasgow and Clyde | 2017-07-04 |
| PF-06463922 for Crizotinib Pretreated ROS1 Positive Non-small-cell Lung Cancer (NCT03439215) | Fondazione Ricerca Traslazionale | 2017-06-13 |
| This Study Tests the New Medicine BI 754111 Alone or in Combination With Another New Substance BI 754091 in Patients With Advanced Cancer. The Study Tests Different Doses to Find the Best Dose for Continuous Treatment. (NCT03156114) | Boehringer Ingelheim | 2017-06-13 |
| The Treatment of Advanced Lung Cancer With Dribbles Antigen by Targeting Activation of Tcells (NCT03057340) | Second Affiliated Hospital, Zhejiang University, School of Medicine | 2017-06-01 |
| Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (NCT03088540) | Regeneron Pharmaceuticals | 2017-05-29 |
| A Study of SHR-1210 in Combination With Pemetrexed and Carboplatin in Subjects With Non-squamous NSCLC (NCT03134872) | Jiangsu HengRui Medicine Co., Ltd. | 2017-05-12 |
| A Study to Assess Programmed Death Ligand-1 (PD-L1) Expression in Cytological Versus Histological Lung Cancer Specimens (NCT03092739) | Hoffmann-La Roche | 2017-05-03 |
| A Study to Evaluate SHR-1210 in Patients With Advanced or Metastatic NSCLC (NCT03085069) | Jiangsu HengRui Medicine Co., Ltd. | 2017-05-03 |
| A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC (NCT03052608) | Pfizer | 2017-04-27 |
| Sublobar Resection Versus Lobectomy for cT1N0M0 Non-small-cell Lung Cancer (NCT03108560) | Shanghai Zhongshan Hospital | 2017-04-18 |
| BIOLUMA: Biomarkers for Nivolumab and Ipilimumab and Evaluation of the Combination in Lung Cancer (NCT03083691) | Lung Cancer Group Cologne | 2017-04-13 |
| Effect of Genetic Polymorphisms on Platinum Based Chemotherapy in Non Small Cell Lung Cancer (NCT03154242) | Ain Shams University | 2017-03-20 |
| Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors (NCT03037385) | Hoffmann-La Roche | 2017-03-17 |